在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Recombinant Human Tumor necrosis factor receptor superfamily member 8 (TNFRSF8), partial

  • 中文名稱:
    人TNFRSF8重組蛋白
  • 貨號:
    CSB-YP023983HU1
  • 規格:
  • 來源:
    Yeast
  • 其他:
  • 中文名稱:
    人TNFRSF8重組蛋白
  • 貨號:
    CSB-EP023983HU1
  • 規格:
  • 來源:
    E.coli
  • 其他:
  • 中文名稱:
    人TNFRSF8重組蛋白
  • 貨號:
    CSB-EP023983HU1-B
  • 規格:
  • 來源:
    E.coli
  • 共軛:
    Avi-tag Biotinylated

    E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.

  • 其他:
  • 中文名稱:
    人TNFRSF8重組蛋白
  • 貨號:
    CSB-BP023983HU1
  • 規格:
  • 來源:
    Baculovirus
  • 其他:

產品詳情

  • 純度:
    >85% (SDS-PAGE)
  • 基因名:
  • Uniprot No.:
  • 別名:
    TNFRSF8; CD30; D1S166E; Tumor necrosis factor receptor superfamily member 8; CD30L receptor; Ki-1 antigen; Lymphocyte activation antigen CD30; CD antigen CD30
  • 種屬:
    Homo sapiens (Human)
  • 蛋白長度:
    Partial
  • 蛋白標簽:
    Tag?type?will?be?determined?during?the?manufacturing?process.
    The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
  • 產品提供形式:
    Lyophilized powder
    Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
  • 復溶:
    We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
  • 儲存條件:
    Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
  • 保質期:
    The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
    Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
  • 貨期:
    Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
    Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
  • 注意事項:
    Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
  • Datasheet :
    Please contact us to get it.

產品評價

靶點詳情

  • 功能:
    Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B.
  • 基因功能參考文獻:
    1. Data suggest that CD4+ T cell-associated HIV-1 RNA is often highly enriched in cells expressing CD30; cells expressing this marker considerably contribute to total pool of transcriptionally active CD4+ lymphocytes in individuals on suppressive anti-retroviral drug therapy; CD30 may be a marker of residual, transcriptionally active HIV-1 infected cells in blood and in gut-associated lymphoid tissue. PMID: 29470552
    2. The stable elevation in classical Hodgkin lymphoma risk with elevated levels of sCD30 and IL6 across 4 or more years prior to diagnosis may also reflect a B-cell-stimulatory environment that promotes the genesis of these cancers. PMID: 28341757
    3. extranodal NK/T-cell lymphoma, nasal type(ENKTL) is the most common type of mature T-cell and NK-cell lymphoma diagnosed at our institution. CD30 is frequently expressed in ENKTL and represents a therapeutic target; however, it may not be a prognostic marker. PMID: 28486951
    4. This study suggests that in patients with CD30+ lymphoproliferative disorders, an aggressive clinical course cannot be defined by the presence of TP63 rearrangements, as was recently shown in systemic ALK negative anaplastic large cell lymphoma. PMID: 27146432
    5. Data suggest that Brentuximab Vedotin (SGN-35) damaged CD30 ligand (CD30L)-immune cells through CD30 extracellular vesicles (EVs). PMID: 27105521
    6. median FoxP3+ Treg count was higher in CD30+ than in CD30- posttransplant lymphoproliferative disorders, 3.0 vs 0 PMID: 29126177
    7. Variant histology is common in pediatric NLPHL, especially types C and E, which are associated with IgD expression. Type C variant histology and possibly type D are associated with decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant increased surveillance, but did not affect overall survival. PMID: 28802087
    8. Expression of CD30 in patients with both DLBCL and other aggressive B-cell lymphomas and the absence of MYC oncogene-driven proliferation in the majority of these tumors suggests that brentuximab may be a particularly effective form of targeted therapy in the subset of patients with high CD30 expression. PMID: 27521276
    9. Prevalence of the CD30 (Ki-1) antigen in human solid tumors was summarized. PMID: 28427526
    10. Higher serum sCD30 levels were associated with an increased risk of bacterial infection after kidney transplantation. PMID: 28122147
    11. CD30 expression was detected in up to 25% of cases of diffuse large B-cell lymphoma and was more frequent in tumors without MYC rearrangement. CD30 expression was not associated with overall survival in R-EPOCH-treated de novo DLBCL patients. PMID: 27816715
    12. CD30 facilitates phosphorylation of heat shock factor 1, activates heat shock promoter element, and induces heat shock protein (HSP) 90. PMID: 27870927
    13. this study shows that polyclonal and allogeneic stimulation induced higher levels of CD30 transcripts in end-stage renal disease patients compared to control patients PMID: 26970513
    14. CD30 expression was not associated with prognosis in our cohort of de novoDLBCL, including in patients who received aggressive chemotherapy. CD30 expression and MYC rearrangement were mutually exclusive in de novoDLBCL. PMID: 26340843
    15. Case Report: CD30 positive lymphomatoid papulosis arising in association with cutaneous amyloidosis in a patient with multiple myeloma. PMID: 26981738
    16. The heterogeneity of CD30 expression in refractory or relapsed peripheral T-cell lymphoma patients indicates the likelihood for better response for patients with strong CD30 expression by tumor cells. PMID: 26703966
    17. CD30 may be useful as a prognostic marker in rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treated DLBCLs, indicating favorable outcomes in a Chinese population. PMID: 26884853
    18. this review is focused on the role of CD30 receptor and p53 as novel targets for therapy in ALK+ ALCL, and also provides an update on their potential involvement in ALK+ ALCL pathogenesis PMID: 26709646
    19. Most angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma-not otherwise specified express variable levels of CD30. PMID: 26574847
    20. Upregulated expression of CD30 is commonly found in sclerosing angiomatoid nodular transformation of the spleen. PMID: 26261484
    21. Our results demonstrated significantly elevated sCD30 levels in AS patients compared to healthy controls (HCs) with mean values of 32.0 +/- 12.2 and 24.9 +/- 8.0 ng/mL, (P(**) = 0.007), suggesting a p role of sCD30 in the pathogenesis of AS. PMID: 26273636
    22. With the introduction of the immunoconjugate brentuximab vedotin, the CD30 antigen has become an effectively targetable molecule. Therefore, we investigated the frequency and level of CD30 expression in post-transplant lymphoproliferative disorders. PMID: 25248878
    23. Data susggest that CD30 antigen may be useful as a prognostic factor and therapeutic target in extranodal natural killer/T-cell lymphoma (NKTCL). PMID: 25288491
    24. Data indicate that CD30 antigen downregulation and P-Glycoprotein (MDR1) upregulation are associated with drug resistance to brentuximab vedotin. PMID: 25840583
    25. Intralymphatic variant of ALCL and LyP may be explained, at least in part, by a particular lymphotropism of the neoplastic cells of cutaneous CD30 lymphoproliferative disorders. PMID: 26371781
    26. BAG-3 expression correlated with increased HSP70 expression in a subset of systemic T cell lymphoma cases co-expressing the CD30 antigen. PMID: 24492285
    27. These results show that high sCD30 levels are independent predictors of graft dysfunction PMID: 25698648
    28. Single threonine residue at position 61 in CD30v that is critical for TRAF2 interaction, NFkappaB activation, and downstream CD30-NFkappaB-dependent phenotypes in hESCs was identified. PMID: 25568342
    29. Case Report: describe a CD30+ lymphoproliferative rash exhibiting a predilection for recurrence on the same skin sites. PMID: 24733405
    30. case Report: primary cutaneous CD30+ anaplastic large cell lymphoma treated successfully with brentuximab vedotin. PMID: 24733422
    31. Elevated serum sCD30 is associated with increased risk of non-Hodgkin lymphoma. PMID: 25567136
    32. Case Report: suggest Sezary syndrome, CD30 anaplastic large-cell lymphoma, and mycosis fungioides are interrelated. PMID: 25548993
    33. levels of serum sCD30 tend to be higher in individuals with atopy. Improvement in lung function seems to be associated with a decrease in sCD30 in children with atopy and troublesome lung symptoms. PMID: 25492095
    34. occurs in a significant subset of angiosarcomas and epithelioid hemangioendotheliomas PMID: 24805132
    35. findings uncover the oncogenic role of the JUNB/CD30 axis and its potential as therapeutic target in ALK+ ALCL. PMID: 25145835
    36. Data indicate a chimeric fusion involving nucleophosmin NPM1 (5q35) and TYK2 kinase (19p13) that encodes an NPM1-TYK2 protein in cutaneous CD30 antigen-positve lymphoproliferative disorders. PMID: 25349176
    37. is expressed in a substantial proportion of DLBCL and CD30 immunohistochemistry may be a useful prognostic marker in R-CHOP treated GCB-DLBCL. PMID: 25135752
    38. The expression of CD30 by mastocytosis mast cells may influence the clinical phenotype and management of mastocytosis. (Review) PMID: 24745678
    39. a substantial subset of patients with T-ALL have lymphoblasts that express surface CD30. CD30 expression by T-lymphoblasts also appears to be up-regulated in patients who are treated with high-dose chemotherapy. PMID: 23937105
    40. Suggest intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis are part of an expanding spectrum of CD30-positive lymphoproliferative disorders. PMID: 24805854
    41. higher serum levels in Ewing sarcoma patients with primary bone tumors PMID: 24375064
    42. diagnostic and prognostic value of CD30 expression in systemic mastocytosis as assessed by multiparameter flow cytometry PMID: 24111625
    43. this study highlights a novel SATB1-p21 axis that plays an important role in the disease progression of cutaneous CD30+LPDs, which provides novel molecular insights into this disease and possibly leads to new therapies in the future. PMID: 24747435
    44. serum concentration during pregnancy is not associated with pre-eclampsia and recurrent pregnancy loss PMID: 23268289
    45. CD30 expression on lymphomatous cells makes an attractive target for drug-conjugated antibody-directed therapies. PMID: 23716537
    46. CD30(+) peripheral T-cell lmyphomas differed significantly from CD30(-) samples. PMID: 23716562
    47. Post-transplant sCD30 serum levels, especially in conjunction with information regarding HLA class II antibodies and serum creatinine levels, provide valuable information regarding graft outcome PMID: 23928467
    48. Malignant Hodgkin and Reed-Sternberg cells release CD30 on the surface of extracellular vesicles facilitating CD30-CD30L interaction between cell types. PMID: 24659185
    49. High pretransplant levels of serum soluble CD30 can be a risk factor for kidney transplant rejection, and its high negative predictive value at various cutoffs make it useful to find candidates with a low risk of acute rejection after transplant. PMID: 23477385
    50. Soluble CD30 levels are significantly reduced in combination immunosuppression but are differentially affected by different immunosuppressant agents. PMID: 23503451

    顯示更多

    收起更多

  • 亞細胞定位:
    [Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Cytoplasm.
  • 組織特異性:
    [Isoform 2]: Detected in alveolar macrophages (at protein level).
  • 數據庫鏈接:

    HGNC: 11923

    OMIM: 153243

    KEGG: hsa:943

    STRING: 9606.ENSP00000263932

    UniGene: Hs.1314



主站蜘蛛池模板: 日韩成av人片在线观看| 18女下面流水不遮图| 人人妻人人澡人人爽人人精品电影 | 精品无码三级在线观看视频| 天天躁日日躁狠狠躁| 精品国产免费一区二区三区香蕉| 国产极品精品自在线| 成人亚洲一区无码久久| 日韩 亚洲 欧美 国产 精品| 亚洲精品久久久久中文字幕| 特级精品毛片免费观看| 少妇精品导航| 日韩国产精品无码一区二区三区| 在线观看无码av网站永久免费| 国产亚洲产品影市在线产品| 国产精品日韩av在线播放| 久久久久国产精品人妻aⅴ牛牛| 顶级欧美熟妇高潮xxxxx| 无码人妻精品一区二区蜜桃色欲| 亚洲综合无码一区二区三区| 午夜免费国产体验区免费的 | 欧美 日韩 亚洲 在线| 奇米777狠狠色噜噜狠狠狠| 日本丰满护士videossexhd| 无码人妻一区二区三区在线| 国产成a人亚洲精品无码樱花| 国产精品色情国产三级在| 亚洲欧美中文字幕日韩一区二区| 国产欧美一区二区三区免费视频| 一本色道久久88综合日韩精品| 亚洲成av人片在www| 久久久橹橹橹久久久久| 日本公妇乱偷中文字幕| 精品一区二区三区免费视频| 国产高潮流白浆免费观看| 亚洲国产区男人本色vr| 22222se男人的天堂| 熟妇熟女乱妇乱女网站| 好吊射视频988gaocom| 久久久亚洲精品成人| 国产免费一区二区三区免费视频|